BPC-157
Reported benefits and downsides
Each item is tagged with the kind of evidence behind it and a strength dial. Read the dial first, the claim second. How we grade evidence strength.
Reported benefits
- Accelerated tendon and ligament healingAnimalLimited evidence
Multiple rat injury-recovery models report faster repair after Achilles and medial-collateral-ligament transection.
- Gut-lesion protectionAnimalLimited evidence
Rat models of ulcerative colitis and gastric ulcers show reduced lesion size with BPC-157 dosing.
- Plausible angiogenic mechanismMechanismModerate evidence
Increases VEGF expression and supports new-blood-vessel growth into damaged tissue in preclinical work.
- Subjective recovery from soft-tissue injuriesAnecdotalAnecdotal only
Recovery reports from athletes and gym users; not controlled trials.
Reported downsides
- Human safety profile is largely unknownUnknownLimited evidence
No completed human RCTs report a defensible adverse-event picture. Long-term effects are uncharacterised.
- Prohibited in competitive sportRegulatoryStrong evidence
On the WADA Prohibited List under S0 (non-approved substances), banned in-competition and out-of-competition.
- No regulated supplyPracticalStrong evidence
Sold online as a 'research chemical'. Independent purity testing finds frequent off-label content, underdosing, and contaminants.
- No data in pregnancy, paediatric, or geriatric populationsUnknownLimited evidence
Default is contraindication by absence of evidence.
Where it works, where it doesn't
Where it works
- Animal injury-recovery research (rodent tendon, gut and muscle models)
- Mechanistic studies of angiogenesis and tissue-repair pathways
Where it doesn't
- Any setting that requires a regulated, pharmaceutical-grade supply
- Competing athletes (WADA-prohibited under S0, non-approved substances)
- Pregnancy, paediatric or geriatric populations (no data)
- Any use that depends on dose-response data we do not yet have in humans
Where the literature comes from
An editorial estimate of the kinds of evidence available for BPC-157, not just what this page cites. Peptide research is rarely RCT-heavy, so the mix matters as much as the volume.
- Preclinical / animal75%
- Mechanism / pharmacology12%
- Case reports / off-label8%
- Regulatory / agency5%
How we estimate this mix: see methodology.
History at a glance
Key moments in the BPC-157 story, from first synthesis through today.
- 1991
First identified from gastric juice
DiscoverySikiric and colleagues isolate the 15-residue pentadecapeptide from human gastric juice and begin characterising its tissue-protective properties.
- 2000
Rodent tendon-healing papers
TrialSeries of rat studies report accelerated tendon and ligament repair after BPC-157 administration.
- 2018
USADA: prohibited in sport
RegulatoryUSADA publishes guidance confirming BPC-157 is on the WADA Prohibited List under S0 (non-approved substances) and banned for athletes.
- 2022
FDA flags BPC-157 in compounding pipeline
RegulatoryFDA-tracked nominations of BPC-157 as a bulk drug substance for compounding under section 503A; status remains contested.
- 2024
US DoD safety advisory
ControversyOperation Supplement Safety publishes 'BPC-157: a prohibited peptide and an unapproved drug' aimed at service members.
- 2026
FDA PCAC review scheduled
MilestonePharmacy Compounding Advisory Committee meeting scheduled for July 2026 to revisit BPC-157 compounding eligibility.
What we know
BPC-157, short for Body Protection Compound 157, is among the most-discussed peptides on the internet and one of the least studied in humans. The compound is a 15-amino-acid fragment of a larger protein originally isolated from human gastric juice in 1991 by Sikiric and colleagues at the University of Zagreb. The Zagreb group has produced most of the published animal work in the three decades since, alongside contributions from collaborators in Asia and the US.
The preclinical literature is genuinely interesting. Rodent studies report accelerated healing of transected Achilles tendons, medial-collateral-ligament injuries, segmental muscle defects, and traumatic brain and spinal-cord injuries. Rodent models of ulcerative colitis, gastric ulcer and short-bowel syndrome also show reduced lesion size and improved recovery with BPC-157 administration. The proposed mechanism, covered in the 'How it works' section, plausibly explains these effects through angiogenesis, growth-factor pathway modulation, nitric-oxide signalling, and gut-brain axis involvement.
Human evidence is essentially absent. There is no published phase-2 or phase-3 randomised controlled trial of BPC-157 for any indication. A handful of small uncontrolled case series and self-report studies exist, but none meets the evidentiary standard the rest of this site applies to peptide-page content. Any 'human dose' or 'effective protocol' quoted online is extrapolated from rodent dose-per-kilogram work to a human-equivalent number, an extrapolation that has not been validated in a controlled trial.
In our coverage area, BPC-157 has no marketing authorisation anywhere. It is not approved by the FDA, the EMA, the MHRA, or any national medicines agency in the EU or EEA. It is supplied online by research-chemical vendors as a vial 'for research use only', a label that does not legalise human use and is not held to pharmaceutical-grade quality standards. See the per-country pages at /regulation for the specific situation in Denmark, Sweden, Norway, Germany, the Netherlands, the UK and the US.
The grey-market supply reality matters. Independent testing of BPC-157 vials sold by online vendors has repeatedly flagged purity, identity and contamination failures: vials containing the wrong molecule entirely, low-purity batches sold as 98%+, generic Certificates of Analysis reused across product lines, and microbial or endotoxin contamination above pharmaceutical limits. The Practical considerations section below lists the verifiable quality signals to look for and the red flags to walk away from. This is harm reduction for readers who already have a product, not an endorsement of grey-market sourcing.
The athletic-doping picture is settled. The World Anti-Doping Agency lists BPC-157 on its Prohibited List under S0 (non-approved substances), meaning it is banned in and out of competition for athletes subject to the WADA Code. USADA has published explicit guidance to US athletes that BPC-157 use can result in sanction. The US Department of Defense's Operation Supplement Safety has warned active-duty service members against use, framing it as an unapproved drug rather than a supplement.
The next regulatory inflection point is the FDA Pharmacy Compounding Advisory Committee meeting scheduled for July 2026, which is expected to revisit BPC-157's eligibility as a bulk drug substance for compounding under section 503A of the Food, Drug & Cosmetic Act. Whatever PCAC recommends, BPC-157 is not an approved medicine today, and the committee's role is to advise on what compounding pharmacies may lawfully prepare rather than to grant marketing authorisation. The decision will shape the US compounding landscape, not the underlying new-drug status.
This page is for education and journalism. We do not advise on starting, stopping, dosing, or sourcing BPC-157, and we do not facilitate the sale of any peptide. The conversation about whether to consider BPC-157 belongs with a clinician who knows your medical history. Use the Practical considerations and Regulation sections below for the operational picture, and the source list for the primary regulatory documents.
How it works
BPC-157 is a 15-amino-acid fragment of a protein found in human gastric juice (the digestive fluid in the stomach). In rodents, it appears to promote angiogenesis (the growth of new blood vessels into damaged tissue) and to modulate growth-factor pathways (the signalling molecules that tell cells when to grow, divide, and repair, such as VEGF, vascular endothelial growth factor, and basic FGF, fibroblast growth factor). It also seems to influence the nitric-oxide system (which controls how blood vessels widen and contract) and the gut-brain axis (the two-way nerve-and-hormone communication between the gut and the central nervous system). Almost all of this is preclinical: most of what we know about how it works comes from rat and cell-culture studies, not from controlled human trials.
Where it acts in the body
- Gastrointestinal tractReduces lesion size in rodent models of gastric ulcer and ulcerative colitis.
- Tendons and ligamentsPromotes repair of transected tendon and medial-collateral-ligament injuries in rats.
- Vascular systemModulates the nitric-oxide pathway and supports angiogenesis (new blood-vessel growth) into damaged tissue.
- Gut-brain axisInfluences communication between gut and central nervous system; mechanism preclinical only.
Safety
Human safety data on BPC-157 is genuinely thin. There are no completed randomised controlled trials that report a defensible adverse-event profile, only small uncontrolled case series and self-reports from athletes and clinic patients. The rodent literature does not flag major acute toxicity at the doses tested, but rodent safety is not human safety, and the metabolic, immune, oncological and longer-term consequences in people remain uncharacterised. The US Department of Defense's Operation Supplement Safety programme (OPSS) and the US Anti-Doping Agency (USADA) have both issued explicit warnings that BPC-157 is an unapproved drug and a substance prohibited in sport. The honest answer to 'is BPC-157 safe?' at this point is 'we do not know, and the absence of evidence is not evidence of absence.'
Is BPC-157 legal where you live?
All countries →| Country | Status |
|---|---|
| Denmark | Not authorised |
| Sweden | Not authorised |
| Norway | Not authorised |
| Germany | Not authorised |
| Netherlands | Not authorised |
| United Kingdom | Not authorised |
| United States | Not approved |
Practical considerations
How the literature has dosed BPC-157, what it costs where it's authorised, how to spot a counterfeit product, and the customs reality. We report. We do not prescribe.
Dosing & administration
No clinical-trial dosing in humans. Animal studies have used subcutaneous, intragastric (oral) and intramuscular routes.
| Context | Range | Reference |
|---|---|---|
| Rodent injury-recovery studies | 10 µg/kg to ~1 mg/kg, varying widely between research groups | Sikiric et al., review of preclinical BPC-157 literature |
| Online vendor-cited 'research doses' (contested) | ≈200–500 µg, once or twice daily SC | Not validated in controlled human work |
There is no defensible human-dose regimen for BPC-157. Any number quoted online or by vendors is extrapolated from rodent studies that were not designed for human translation. We do not recommend a dose; we report what the literature has used so readers can interpret what they see online.
Quality verification
There is no legitimate regulated supply chain for BPC-157 anywhere we cover. Independent testing of grey-market vials regularly finds purity, identity and contamination failures. The guidance below is harm reduction for readers who have already obtained a product. It is not an endorsement of grey-market sourcing.
What legitimate products show
- A batch-specific Certificate of Analysis (COA), not a generic template, with a date and lot number that match the product
- Reverse-phase HPLC purity figure ≥98% with the chromatographic method disclosed
- Identity testing by mass spectrometry confirming the BPC-157 sequence (purity without identity testing is meaningless)
- Bacterial endotoxin and microbiological testing within USP limits
- An ISO 17025-accredited third-party laboratory issuing the COA
Counterfeit red flags
- Generic COAs copy-pasted across multiple products from the same vendor
- Purity figures with no method described, or 'area %' reported as purity
- No identity testing at all (vial could be 99% pure but of the wrong molecule)
- Vendor refuses to share batch-specific COAs on request
- Prices substantially below the typical market range, often a counterfeit signal
Travel & customs
Travelling across borders with BPC-157 carries a real customs-detention risk because it is an unauthorised medicine in every country we cover. Some travellers report routine clearance, others report seizure and follow-up enforcement. We do not advise readers to attempt it.
Vendor reviews launching Q3 2026
We order from vendors ourselves, send samples to an independent lab, and publish what we find, including the ones that get it wrong. BPC-157-specific vendor reviews will live here when the testing programme is live. Until then, please assume any online seller is unverified.
Latest updates
No recent updates logged. Regulatory and trial milestones for BPC-157 will land here as they happen.
Frequently asked
Is BPC-157 approved for human use anywhere?
No. It is not authorised as a medicine by the FDA, EMA, MHRA, or any national agency we cover. It is sold online as a 'research chemical' or 'not for human use' product. That labelling does not legalise human use, does not put the product through pharmaceutical-quality controls, and does not change the regulatory status.
Does the human evidence support the claims made for BPC-157?
Not yet. There is no published randomised controlled trial of BPC-157 for any indication. The rodent literature is extensive and often positive, but rodent results do not automatically translate to humans, and the 'human equivalent doses' quoted online are extrapolations, not data.
What is a safe or effective dose of BPC-157 in humans?
There is no defensible answer. The published human dose-finding work that would establish one does not exist. Online sources commonly cite 200-500 µg one or twice daily SC, extrapolated from rodent µg/kg studies, but this has not been validated in controlled trials.
Is BPC-157 legal to possess?
Possession sits in a grey area across our coverage area. BPC-157 is an unauthorised medicine, not a scheduled controlled substance, so simple possession is generally not a drug-scheduling offence. Sale and supply, including online sale to consumers, is what regulators target. See the country pages for jurisdiction-specific detail.
Why is there so little research, if the rodent data is so promising?
Three reasons commonly cited. BPC-157 is no longer patentable, removing the commercial incentive for an expensive trial programme. The FDA and other regulators treat unapproved peptides under the new-drug framework, which raises the bar for a human trial. And much of the academic interest has been concentrated in a small number of research groups. Plenty of compounds with promising animal data have not progressed for similar structural reasons.
What is happening with the FDA Pharmacy Compounding Advisory Committee in 2026?
The PCAC is scheduled to meet in July 2026 and revisit BPC-157's eligibility as a bulk drug substance for compounding under section 503A. The committee advises the FDA on what compounders may lawfully prepare; it does not grant marketing authorisation. Whatever the outcome, BPC-157 remains unapproved as a medicine until a new-drug application succeeds, which is a separate and much longer process.
Glossary
Quick definitions for the technical terms used on this page. Hover any term in the body text and most browsers show the same definition; this section is the canonical reference.
- Angiogenesis
- The growth of new blood vessels into tissue. One of the proposed mechanisms behind BPC-157's repair effects.
- Certificate of Analysis (COA)
- A laboratory-issued document detailing a product's purity, identity and other quality measures for a specific batch.
- HPLC
- High-performance liquid chromatography. The standard analytical technique for measuring peptide purity.
- Mass spectrometry (MS)
- An analytical technique that measures a molecule's mass and fragmentation, used to confirm a peptide's identity.
- Pentadecapeptide
- A peptide that is 15 amino acids long.
- Preclinical
- Research conducted before human trials, typically in animals or cell culture.
- USP
- United States Pharmacopeia. The compendial standard that sets purity, identity and contamination limits for medicines and ingredients.
- WADA
- World Anti-Doping Agency. Maintains the Prohibited List that anti-doping bodies enforce across sport.
Follow BPC-157 updates
New trial readouts, regulatory shifts, vendor-test results: get a short email when something meaningful happens on BPC-157. We don't spam, sell your address, or pad the list with promotions.
We'll only email about BPC-157. Per-peptide alerts launch with our newsletter pipeline in Q3 2026; until then we hold your address for that list and nothing else.
In the conversation
Credentialed experts and podcasters who have covered BPC-157 on the record. We link the original source, attribute by full name, and disclose any conflict of interest. We do not paraphrase as if it were our work.
Attia covers BPC-157 from [57:45] through [1:03:15], placing it in what he calls 'bucket #1' — peptides characterised by uncertain origins, broad claims, weak mechanistic evidence, and failure to replicate animal data in humans. The episode's overall framing: 'The big picture is that peptides are a legitimate, powerful class of therapeutics, but the legitimacy is confined to a relatively narrow subset of them.' BPC-157 sits outside that subset.
Conflict of interest: Operates Early Medical longevity clinic with GLP-1 prescribing line; Momentous supplement-line affiliation; content and book businesses.
Listen→ at 00:57:45
Topol places BPC-157 in his 'Non-Approved Peptides' summary table and discusses it briefly in the context of public advocacy from RFK Jr. The category-level concern he raises across non-approved peptides is the theoretical cancer-risk signal from growth-promoting compounds plus the absence of trial-grade dose, purity and long-term safety data. The piece's bottom line: 'The peptide craze is unfounded. The evidence base for use of these drugs, either for off-label indications or as non-approved drugs, is wanting.'
Read→
Tatem, a fellowship-trained men's-health urologist, argues that the FDA 'silently banned 19 peptides overnight' — referring to the 2023 Category 2 listing that included BPC-157 and ipamorelin — and frames the restriction as Big Pharma-driven suppression with 'RFK Jr. reversing it all.' We report his framing because it represents a popular counter-narrative readers will encounter. We do not endorse it: the 2023 listing followed FDA's published safety review process, the 2026 PCAC meeting is the actual procedural channel for revisiting BPC-157 specifically, and 'Big Pharma is hiding this' framing collapses the distinction between safety review and commercial suppression. The episode title is the host's standard clickbait format, not Tatem's words.
Conflict of interest: Paid advisor and consultant relationships with Boston Scientific, Coloplast and Endo Pharmaceuticals; runs a men's-health clinic with commercial interest in hormone and peptide-adjacent therapies.
Listen→
Huberman discloses he has taken BPC-157 personally for joint pain and gives this two-sentence summary of the evidence picture: 'I'm not aware of a single adverse event. I'm also not aware of a single clinical trial in humans. There's one which looked at gut health but it's not not a great study.' He attributes the missing trials to commercial structure — 'there is a company that owns the patent, but they're just not interested in the drug enough... to pursue it' — and notes that 'It's hard to get really true BPC57 now.' We report the 'no adverse events' framing because Huberman said it, but flag plainly: absence of adverse-event reports in an essentially untrialed compound is not evidence of safety, and is materially different from a characterised safety profile.
Conflict of interest: Tier 3 reflects the goop platform context (history of medical-claim controversies), Huberman's personal-anecdote framing in this segment, and the absence of explicit primary-source citations. Huberman's own commercial relationships include the Momentous supplement line and a long track record of supplement-company sponsorships.
Watch→